Clearside Biomedical, Inc. (NASDAQ:CLSD) management will conduct a conference call for 10th August 2020 at 4:30 PM Eastern Time to discuss financial results and companys performance for 2Q20.
The conference call will also be available live on the website www.clearsidebio.com
Earnings Expectation
Clearside Biomedical, Inc. is set to announce second quarter earning results on Monday 10th August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, CLSD to report 2Q20 loss of $ 0.12 per share. For the full year, analysts anticipate top line of $ 7.81 million, while looking forward to loss of $ 0.44 per share bottom line.
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
